Month: February 2022

LOS ANGELES, Feb. 24, 2022 (GLOBE NEWSWIRE) — Versus Systems Inc. (“Versus” or the “Company”) (NASDAQ: VS) today announced the pricing of its public offering of 4,375,000 units for gross proceeds of USD $7,000,000, before deducting underwriting discounts and commissions and other offering expenses payable by Versus. Each unit consists of one common share, no par value per share, and one warrant to purchase one common share, at a public offering price of $1.60 per unit and a warrant exercise price of $1.92. All of the shares and warrants included in this offering are being sold by Versus. In addition, Versus has granted the underwriters a 30-day option to purchase up to an additional 656,250 common shares and/or 656,250 additional warrants at the public offering price, in any combination thereof, on the same terms as the other common...

LAS VEGAS, Feb. 24, 2022 (GLOBE NEWSWIRE) — MusclePharm Corporation (“MusclePharm” or the “Company”) (OTCMKTS: MSLP), a global provider of leading sports nutrition and lifestyle branded nutritional supplements, today announced it has entered into a partnership with Costco US for the distribution of the Company’s energy drink line, MP Combat Energy. The partnership will begin in the summer of 2022 in Costco locations across Southern California and Hawaii and MusclePharm expects to move to a full roll-out in 2023. MP Combat Energy will be available for purchase in a 24-variety pack made up of 3 flavors: Grapefruit Lime, Green Apple and Black Cherry. Mr. Ryan Drexler, the Chairman of the Board and Chief Executive Officer of MusclePharm, stated, “This will be MusclePharm’s first partnership for our energy drink line with a food wholesaler...

The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio and Establishes Growth Platform in Neurology RALEIGH, N.C., Feb. 24, 2022 (GLOBE NEWSWIRE) — BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM (celecoxib oral solution), the first and only FDA-approved ready-to-use oral solution for the acute treatment of migraine with or without aura in adults. “ELYXYB represents a significant innovation in the rapidly growing migraine market and our initial entry into the Neurology space, which is complementary to our current sales and marketing efforts,”...

DUARTE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — iPower Inc. (Nasdaq:IPW) (“iPower” or the “Company”), one of the leading online hydroponic equipment suppliers and retailers, held its Annual Meeting of Stockholders yesterday, February 23, 2022. All Company proposals were approved by the Company’s stockholders, including: the election of five directors to serve for a term of one year; ratification of the Company’s independent auditors, UHY, LLP; approval of the Company’s executive compensation; and approval of the Company’s stockholder’s ability to determine the frequency of an advisory vote on the Company’s executive compensation. About iPower Inc. iPower Inc. is one of the leading online retailers and suppliers of hydroponics equipment and accessories. iPower offers thousands of stock keeping units from its in-house brands as...

Live with Unicorn Hunters Episode 11 Vastmindz Live with Unicorn Hunters Episode 11 VastmindzEhave has licensed AI technology from Vastmindz for MetaHealthU. in 2022, Ehave plans to monetize the AI technology it licensed from Vastmindz to expand the Ehave Dashboard in the MetaHealthU offering to identify an individual’s physiological condition, such as Heart Rate, Heart Rate Variability (HRV), Respiration Rate, Oxygen Saturation Level, and other vital statistics. Unicorn Hunters is a global platform with an audience of more than 14.5 million viewers around the world. Vastmindz, an AI-driven tech company that democratizes access to health and wellness data for humans & animals using innovative computer vision technology.MIAMI, Feb. 24, 2022 (GLOBE NEWSWIRE) — Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading...

TORONTO, Feb. 24, 2022 (GLOBE NEWSWIRE) — ARHT Media Inc. (“ARHT Media“) [TSXV:ART], the global leader in the development, production and distribution of high-quality, low latency hologram and digital content, announces today that it has granted an aggregate of 600,000 options to two directors pursuant to the Company’s stock option plan. The stock options vest in the following schedule: 1/3 immediately, 1/3 on the first anniversary of the grant; and 1/3 on the second anniversary of the grant, and may be exercised at a price of $0.245 for a period of five years from the date of grant. The grant of options is subject to the approval of the TSX Venture Exchange. ARHT would also like to announce the resignation of Kwok Hei (Benjamin) Yam from the board of directors. Larry O’Reilly said, “We would like...

Revisiting the risk of tardive dyskinesia with metoclopramide use in diabetic gastroparesis: results of a real-world data driven epidemiology study SOLANA BEACH, Calif., and CHICAGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on Gimoti (metoclopramide) nasal spray (GIMOTI), today announced that the results of a retrospective analysis of United States (US) administrative claims data that examined the association between tardive dyskinesia (TD) and potential risk factors will be presented at the annual Digestive Disease Week Meeting in San Diego, CA taking place from May 21-24, 2022. Evoke’s flagship product, GIMOTI, is an FDA-approved novel nasal formulation of metoclopramide commercially...

Carrollton, Texas, Feb. 24, 2022 (GLOBE NEWSWIRE) — Allied Energy Corp (OTC Pink: AGYP), is a producing oil and gas company focused on leasing and reworking of oil and gas reserves in one of the most prolific hydrocarbon areas in the United States. Allied Energy is pleased to announce that the Company has retained the services of a securities council to assist the company “AGYP” in the process of up-listing to a recognized North American Stock Exchange, excluding the US OTCMarkets. Furthermore, council has also been secured to advise and help structure an ongoing share buyback program of AGYP’s common stock. Council retained by Allied has practiced securities law for over 30 years in North America and has successfully helped companies list and up-list their securities from lower tiered exchanges to higher tiered exchanges....

FORT LAUDERDALE, FL, Feb. 24, 2022 (GLOBE NEWSWIRE) — SFLMaven Corp. (OTC Pink: SFLM), (“SFLMaven” or the “Company”) (www.sflmaven.com), a leading provider of high-end luxury goods, is pleased to provide current and prospective shareholders with an update on performance as well as qualitative and quantitative guidance for the Company’s outlook ahead. “When we closed last year, we pointed to a number of key tailwinds driving our jewelry business that could factor into accelerating growth in 2022,” stated Joseph Ladin, CEO of SFLMaven. “So far, that seems to be playing out this year, with our Q1 performance putting us on pace for double-digit organic growth, which helps to lay a sturdy foundation as we expand into new domains, including non-fungible tokens and the Metaverse.” Management notes that the Company...

Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed to be the first to demonstrate robust neutralizing antibody responses in mucosal sites, which is where primary infection occurs Vaxart’s S-only candidate induced a 1000-fold increase in nasal IgA responses to the variants, which could have substantial impact on reducing community transmission SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — A new study published on BioRxiv.org demonstrates that Vaxart’s S-only COVID-19 clinical vaccine candidate, now being studied by Vaxart in Phase II trials, generated antibodies to the original COVID-19 virus strain and to the beta, delta, alpha and gamma variants of SARS-CoV-2 in the serum and nasal mucosa of non-human primates (NHPs). The NHP results...